Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Augusta SpinCo Corp incurred term loan of up to $4 billion with Barclays Bank PLC (as administrative agent) at alternate base rate or Term SOFR rate, in each case, plus an applicable margin maturing Tranche 1 matures 364 days after the Closing Date and Tranche 2 matures on the second anniversary of the Closing Date.
- Instrument
- term loan
- Principal
- up to $4 billion
- Counterparty
- Barclays Bank PLC (as administrative agent)
- Rate
- alternate base rate or Term SOFR rate, in each case, plus an applicable margin
- Maturity
- Tranche 1 matures 364 days after the Closing Date and Tranche 2 matures on the second anniversary of the Closing Date
- Event
- incurrence
Exact text from the filing
and the Merger Agreement will be consummated is referred to as the “Acquisition Effective Date”. The Credit Agreement provides the Company with the ability to borrow up to $4 billion on an unsecured basis to finance a cash distribution to BD in connection with the transaction (the “BD Special Cash Payment”) and related fees and expenses, and any proceeds in
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Augusta SpinCo Corp entered into Term Loan Credit Agreement with Barclays Bank PLC valued at $4,000,000,000 (effective 2026-01-08).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Barclays Bank PLC
- Value
- $4,000,000,000
- Effective
- 2026-01-08
Exact text from the filing
On January 8, 2026 (the “Effective Date”), Augusta SpinCo Corporation (the “Company”), a wholly owned subsidiary of Becton, Dickinson and Company (“BD”), entered into a Term Loan Credit Agreement with the lenders named therein, Barclays Bank PLC, as administrative agent, and the other parties party thereto (the “Credit Agreement”), in connection with the pending combination of BD’s Biosciences and Diagnostic Solutions business (the “Biosciences and Diagnostic Solutions Business”) with Waters Corporation (“Waters”) in a Reverse Morris Trust transaction pursuant to (x) the Separation Agreement, dated as of July 13, 2025 (the “Separation Agreement”), by and among Waters, BD and the Company and (y) the Agreement and Plan of Merger, dated as of July 13, 2025 (the “Merger Agreement”), by and among Waters, BD and the Company and Beta Merger Sub, Inc., a wholly owned subsidiary of Waters.
View on SEC.gov